Cited by 3,421Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 303 of the 309 references it cites were found in a registry or an index.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Open access

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.·2016·Annals of Oncology

DOI 10.1093/annonc/mdw235

Open this paper in CoChat — free account Open PDF

Abstract

Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw235

Cites

303 of 303 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova‐Foucher, E., Lortet‐Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,243
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citation
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
Fong, Y., Fortner, J. G., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,722

Show all 309 references

Research works printed but not linked: 6

Stintzing, 2013, Analysis of KRAS/NRAS and BRAF mutations in FIRE-3, Eur J Cancer, 49
Venook, 2014, J Clin Oncol, 32
Collettini, 2012, Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates, Rofo, 184, 316
Lenz, 2014, Ann Oncol, 25
Garcia Alfonso, 2014, Ann Oncol, 25
Cascinu, 2015, Eur J Cancer, 51

Sorted by citations

Items 501–600 of 1,003

SHP2 associates with nuclear localization of STAT3: significance in progression and prognosis of colorectal cancer
Huang, Y., Wang, J., Cao, F., Jiang, H., Li, A., Li, J., Qiu, L., Shen, H., Chang, W., Zhou, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17604-7 · Cited by 35
Pulmonary Thermal Ablation Enables Long Chemotherapy-Free Survival in Metastatic Colorectal Cancer Patients
Fonck, M., Perez, J.-T., Catena, V., Bécouarn, Y., Cany, L., Brudieux, E., Vayre, L., Texereau, P., Brun-Ly, V. L., Verger, V., et al. (2018) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-018-1939-7 · Cited by 35
Long‐Term Outcome After Conventional Two‐Stage Hepatectomy Versus Tourniquet‐ALPPS in Colorectal Liver Metastases: A Propensity Score Matching Analysis
Robles-Campos, R., Brusadín, R., López‐Conesa, A., López‐López, V., Navarro‐Barrios, Á., López-Espín, J. J., Perez, J. A., & Parrilla, P. (2019) · World Journal of Surgery · doi:10.1007/s00268-019-05031-w · Cited by 35
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
Belli, V., Matrone, N., Napolitano, S., Migliardi, G., Cottino, F., Bertotti, A., Trusolino, L., Martinelli, E., Morgillo, F., Ciardiello, D., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1230-z · Cited by 36
Self-citation
BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study
Mas, L., Bachet, J., Taly, V., Bouché, O., Taı̈eb, J., Cohen, R., Meurisse, A., Normand, C., Gornet, J., Artru, P., et al. (2019) · Cancers · doi:10.3390/cancers11070998 · Cited by 35
Self-citation
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer
Gockel, I., Jansen‐Winkeln, B., Haase, L., Niebisch, S., Moulla, Y., Lyros, O., Lordick, F., Schierle, K., Wittekind, C., & Thieme, R. (2019) · Tumori Journal · doi:10.1177/0300891619868013 · Cited by 35
Mucinous adenocarcinoma of the colon and rectum: A genomic analysis
Reynolds, I. S., O’Connell, E., Fichtner, M. W., McNamara, D. A., Kay, E. W., Prehn, J. H. M., Furney, S. J., & Burke, J. P. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25764 · Cited by 35
Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial.
Ren, C., Mai, Z.-J., Jin, Y., He, M.-M., Wang, Z., Luo, H., Zhang, D., Wu, C.-Y., Wang, F., & Xu, R. (2020) · PubMed Central · Cited by 35
Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial
Bragagnoli, A. S. C., Araújo, R. L. C., Ferraz, M. W. S., dos Santos, L. V., Abdalla, K. C., Comar, F., Santos, F. A., de Oliveira, M. A., Carvalheira, J. B. C., Cárcano, F. M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01208-6 · Cited by 36
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
Vitiello, P. P., Martini, G., Mele, L. L., Giunta, E. F., Falco, V. D., Ciardiello, D., Belli, V., Cardone, C., Matrone, N., Poliero, L., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01811-8 · Cited by 35
Self-citation
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
Patelli, G., Vaghi, C., Tosi, F., Mauri, G., Amatu, A., Massihnia, D., Ghezzi, S., Bonazzina, E. F., Bencardino, K. B., Cerea, G., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00795-5 · Cited by 39
Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
Ciardiello, D., Martini, G., Famiglietti, V., Napolitano, S., Falco, V. D., Troiani, T., Latiano, T. P., Ros, J., Élez, E., Vitiello, P. P., et al. (2021) · Cancers · doi:10.3390/cancers13081941 · Cited by 36
Self-citation
Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?
Sumransub, N., Vantanasiri, K., Prakash, A., & Lou, E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.001 · Cited by 36
NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?—Case series and review of the literature
Osumi, H., Vecchione, L., Keilholz, U., Vollbrecht, C., Alig, A. H. S., von Einem, J. C., Stahler, A., Striefler, J. K., Kurreck, A., Kind, A. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.010 · Cited by 38
Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer
Avallone, A., Piccirillo, M. C., Nasti, G., Rosati, G., Carlomagno, C., Gennaro, E. D., Romano, C., Tatangelo, F., Granata, V., Cassata, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.18475 · Cited by 37
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial
Ychou, M., Rivoire, M. L., Thézenas, S., Guimbaud, R., Ghiringhelli, F., Mercier-Blas, A., Mineur, L., François, É., Khemissa, F., Chauvenet, M., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01644-y · Cited by 37
Self-citation
The Role of Conventional TACE (cTACE) and DEBIRI-TACE in Colorectal Cancer Liver Metastases
Vogl, T. J., & Lahrsow, M. (2022) · Cancers · doi:10.3390/cancers14061503 · Cited by 35
Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy
Price, T., Ang, A., Boedigheimer, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Satya Suresh, A., Thomas, A., Tjulandin, S., et al. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1798695 · Cited by 33
Self-citation
De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity
Moosavi, S. H., Eide, P. W., Eilertsen, I. A., Brunsell, T. H., Berg, K. C. G., Røsok, B. I., Brudvik, K. W., Bjørnbeth, B. A., Guren, M. G., Nesbakken, A., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00956-1 · Cited by 34
Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer
Costa, B. F., Estrada, M. F., Gomes, A. P., Fernandez, L. M., Azevedo, J., Póvoa, V., Fontes, M., Alves, A., Galzerano, A., Castillo-Martín, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49051-0 · Cited by 40
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
Martinelli, E., Sforza, V., Cardone, C., Capasso, A., Nappi, A. G., Martini, G., Napolitano, S., Rachiglio, A. M., Normanno, N., Cappabianca, S., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000177 · Cited by 34
Self-citation
In Vitro Anticancer Efficacy of Six Different Clinically Approved Types of Liquids Exposed to Physical Plasma
Freund, E., Liedtke, K. R., Gebbe, R., Heidecke, A., Partecke, L.-I., & Bekeschus, S. (2019) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2019.2902015 · Cited by 34
RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer
Matsumoto, A., Shimada, Y., Nakano, M., Oyanagi, H., Tajima, Y., Nakano, M., Kameyama, H., Hirose, Y., Ichikawa, H., Nagahashi, M., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7561 · Cited by 34
Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study
Dyhl-Polk, A., Schou, M., Vistisen, K. K., Sillesen, A., Serup‐Hansen, E., Faber, J. O., Klausen, T. W., Bojesen, S. E., Vaage‐Nilsen, M., & Nielsen, D. L. (2020) · The Oncologist · doi:10.1002/onco.13536 · Cited by 34
The Evolving Roles of Bacopa monnieri as Potential Anti-Cancer Agent: A Review
Ghosh, S., Khanam, R., & Chowdhury, A. A. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1841248 · Cited by 36
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer
Arai, H., Xiao, Y., Loupakis, F., Kawanishi, N. K., Wang, J., Battaglin, F., Soni, S., Zhang, W., Mancao, C., Salhia, B., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001714 · Cited by 34
Self-citation
Biomarkers for Malignant Pleural Mesothelioma—A Novel View on Inflammation
Vogl, M., Rosenmayr, A., Bohanes, T., Scheed, A., Brndiar, M., Stubenberger, E., & Ghanim, B. (2021) · Cancers · doi:10.3390/cancers13040658 · Cited by 33
Targeting KRAS in Colorectal Cancer
Wang, C., & Fakih, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01022-0 · Cited by 35
A new rapid diagnostic system with ambient mass spectrometry and machine learning for colorectal liver metastasis
Kiritani, S., Yoshimura, K., Arita, J., Kokudo, T., Hakoda, H., Tanimoto, M., Ishizawa, T., Akamatsu, N., Kaneko, J., Takeda, S., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08001-5 · Cited by 34
A Versatile Theranostic Platform for Colorectal Cancer Peritoneal Metastases: Real‐Time Tumor‐Tracking and Photothermal‐Enhanced Chemotherapy
Sun, T., Zhang, G., Ning, T., Chen, Q., Chu, Y., Luo, Y., You, H., Su, B., Li, C., Guo, Q., et al. (2021) · Advanced Science · doi:10.1002/advs.202102256 · Cited by 34
3D Quantitative Ablation Margins for Prediction of Ablation Site Recurrence After Stereotactic Image-Guided Microwave Ablation of Colorectal Liver Metastases: A Multicenter Study
Ruiter, S. J. S., Tinguely, P., Paolucci, I., Engstrand, J., Candinas, D., Weber, S., de Haas, R. J., de Jong, K. P., & Freedman, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.757167 · Cited by 35
A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research
Wensink, G. E., Bond, M. J. G., Küçükköse, E., May, A. M., Vink, G. R., Koopman, M., Kranenburg, O., & Roodhart, J. M. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102174 · Cited by 35
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
Belli, V., Sforza, V., Cardone, C., Martinelli, E., Barra, G., Matrone, N., Napolitano, S., Morgillo, F., Tuccillo, C., Federico, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20054 · Cited by 33
Self-citation
Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma
Thomsen, C. B., Hansen, T. F., Andersen, R. F., Lindebjerg, J., Jensen, L. H., & Jakobsen, A. K. M. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0723-5 · Cited by 34
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
Martinelli, E., Troiani, T., Sforza, V., Martini, G., Cardone, C., Vitiello, P. P., Ciardiello, D., Rachiglio, A. M., Normanno, N., Bianchi, A. S., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000299 · Cited by 34
Self-citation
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab
van Dijk, E., Biesma, H. D., Cordes, M., Smeets, D., Neerincx, M., Das, S., Eijk, P. P., Murphy, V., Barat, A., Bacon, O., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.1782 · Cited by 33
Self-citation
Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison
Claassen, Y. H. M., Vermeer, N. C. A., Iversen, L. H., Eycken, E. V., Guren, M. G., Mroczkowski, P., Martling, A., Cazador, A. C., Johansson, R., Vandendael, T., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0215-6 · Cited by 33
Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies
Hass, P., Mohnike, K., Kropf, S., Brunner, T. B., Walke, M., Albers, D., Petersen, C., Damm, R., Walter, F., Ricke, J., et al. (2019) · Brachytherapy · doi:10.1016/j.brachy.2019.08.003 · Cited by 33
Self-citation
Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases
Baratti, D., D, S. K. M., Niger, M., Perrone, F., Milione, M., Cattaneo, L., Guagliò, M., Bartolini, V., Pietrantonio, F., & D, M. D. M. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09161-7 · Cited by 33
Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease
Tselikas, L., Garzelli, L., Mercier, O. M., Auperin, A., Lamrani, L., Deschamps, F., Yevich, S. M., Roux, C., Mussot, S., Delpla, A., et al. (2020) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2020.09.006 · Cited by 33
Age disparities in stage‐specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK ‐2 population‐based study
Pilleron, S., Charvat, H., Araghi, M., Arnold, M., Fidler-Benaoudia, M. M., Bardot, A., Guren, M. G., Tervonen, H. E., Little, A. L., O’Connell, D. L., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33326 · Cited by 33
Emerging applications of radiomics in rectal cancer: State of the art and future perspectives
Hou, M., & Sun, J. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i25.3802 · Cited by 33
Very Early Recurrence After Liver Resection for Colorectal Metastases: Incidence, Risk Factors, and Prognostic Impact
Viganò, L., Gentile, D., Galvanin, J., Corleone, P., Costa, G., Cimino, M., Procopio, F., & Torzilli, G. (2021) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-021-05123-w · Cited by 33
Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Tonello, M., Baratti, D., Sammartino, P., Giorgio, A. D., Robella, M., Sassaroli, C., Framarini, M., Valle, M., Macrì, A., Graziosi, L., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11045-3 · Cited by 35
Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
Hu, L., Lan, H., Huang, D., Li, X., & Jin, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769305 · Cited by 34
In vitro additive antitumor effects of dimethoxycurcumin and 5‐fluorouracil in colon cancer cells
Zhao, H., Liu, Q., Wang, S., Dai, F., Cheng, X., Cheng, X.-B., Chen, W., Zhang, M., & Chen, D. (2017) · Cancer Medicine · doi:10.1002/cam4.1114 · Cited by 33
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
Goey, K. K. H., Sørbye, H., Glimelius, B. L. G., Adams, R., André, T., Arnold, D., Berlin, J. D., Bodoky, G., de Gramont, A., Díaz‐Rubio, E., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.010 · Cited by 34
Self-citation
Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study
Taniguchi, H., Okamoto, W., Muro, K., Akagi, K., Hara, H., Nishina, T., Kajiwara, T., Denda, T., Hironaka, S., Kudo, T., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.10.004 · Cited by 33
Self-citation
Natural language processing of German clinical colorectal cancer notes for guideline-based treatment evaluation
Becker, M., Kasper, S., Böckmann, B., Jöckel, K., & Virchow, I. (2019) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2019.04.022 · Cited by 33
Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches
Atreya, C. E., Yaeger, R., & Chu, E. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175679 · Cited by 35
Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer
Zou, Q., Lei, X., Xu, A., Li, Z., He, Q., Huang, X., Xu, G., Tian, F., Ding, Y., & Zhu, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.724139 · Cited by 33
Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation
Smits, M. L. J., Bruijnen, R. C. G., Tetteroo, P. M., Vonken, E.-J. P. A., Meijerink, M. R., Hagendoorn, J., de Bruijne, J., & Prevoo, W. (2023) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-023-03545-4 · Cited by 32
Deep learning models for automatic tumor segmentation and total tumor volume assessment in patients with colorectal liver metastases
Wesdorp, N. J., Zeeuw, M. J., Postma, S. C. J., Roor, J., van Waesberghe, J. H. T. M., van den Bergh, J. E., Nota, I., Moos, S. I., Kemna, R., Vadakkumpadan, F., et al. (2023) · European Radiology Experimental · doi:10.1186/s41747-023-00383-4 · Cited by 37
Self-citation
Multicenter and inter-software evaluation of ablative margins after thermal ablation of colorectal liver metastases
Laimer, G., Verdonschot, K. H. M., Kopf, L., van der Lei, S., Scharll, Y., Hannink, G., Jenniskens, S. F. M., Meijerink, M. R., Bale, R. J., & Overduin, C. G. (2024) · European Radiology · doi:10.1007/s00330-024-10956-5 · Cited by 32
Predictive model for high‐frequency microsatellite instability in colorectal cancer patients over 50 years of age
Fujiyoshi, K., Yamaguchi, T., Kakuta, M., Takahashi, A., Arai, Y., Yamada, M., Yamamoto, G., Ohde, S., Takao, M., Horiguchi, S., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1088 · Cited by 32
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Cremolini, C., Re, M. D., Antoniotti, C., Lonardi, S., Bergamo, F., Loupakis, F., Borelli, B., Marmorino, F., Citi, V., Cortesi, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23559 · Cited by 32
Self-citation
MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach
Schmoll, H., Arnold, D., de Gramont, A., Ducreux, M. P., Grothey, A. F., O'Dwyer, P. J., Cutsem, E. V., Hermann, F., Bosanac, I., Bendahmane, B., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2632-6 · Cited by 32
Self-citation
Stereotactically navigated percutaneous microwave ablation (MWA) compared to conventional MWA: a matched pair analysis
Beyer, L. P., Lürken, L., Verloh, N., Haimerl, M., Michalik, K., Schaible, J., Stroszczynski, C., & Wiggermann, P. (2018) · International Journal of Computer Assisted Radiology and Surgery · doi:10.1007/s11548-018-1778-7 · Cited by 32
The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases
Goffredo, P., Utria, A. F., Beck, A. C., Chun, Y. S., Howe, J. R., Weigel, R. J., Vauthey, J., & Hassan, I. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3978-4 · Cited by 32
Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials
Modest, D. P., Rivera, F., Bachet, J., de Braud, F., Pietrantonio, F., Koukakis, R., Demonty, G., & Douillard, J.-Y. (2019) · International Journal of Cancer · doi:10.1002/ijc.32110 · Cited by 32
Self-citation
Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer
Moik, F., Posch, F., Grilz, E., Scheithauer, W., Pabinger, I., Prager, G. W., & Ay, C. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.01.002 · Cited by 32
Self-citation
ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study
Bednarsch, J., Czigány, Z., Sharmeen, S., van der Kroft, G., Strnad, P., Ulmer, T. F., Isfort, P., Bruners, P., Lurje, G., & Neumann, U. P. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01919-3 · Cited by 32
Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer
Walter, T., Hawkins, N., Pollock, R. F., Colaone, F., Shergill, S., & Ross, P. J. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03315-6 · Cited by 33
Practical considerations in the use of regorafenib in metastatic colorectal cancer
Loupakis, F., Antonuzzo, L., Bachet, J., Kuan, F., Macarulla, T. M., Pietrantonio, F., Xu, R., Taniguchi, H., Winder, T. L., Yuki, S., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920956862 · Cited by 33
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives
Folprecht, G., Martinelli, E., Mazard, T., Modest, D. P., Tsuji, A., Esser, R., Cremolini, C., & Falcone, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102301 · Cited by 31
Self-citation
Software-based assessment of tumor margins after percutaneous thermal ablation of liver tumors: A systematic review
Minier, C., Hermida, M., Allimant, C., Escal, L., Pierredon-Foulongne, M. A., Belgour, A., Piron, L., Taourel, P., Cassinotto, C., & Guiu, B. (2022) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2022.02.004 · Cited by 32
Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
Amatu, A., Mauri, G., Tosi, F., Bencardino, K. B., Bonazzina, E. F., Gori, V., Ruggieri, L., Arena, S., Bardelli, A., Marsoni, S., et al. (2022) · Cancers · doi:10.3390/cancers14051197 · Cited by 33
Self-citation
Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer
Tan, E. S., Fan, W., Knepper, T. C., Schell, M. J., Şahin, İ. H., Fleming, J. B., & Xie, H. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00898-7 · Cited by 32
Exosomal circPABPC1 promotes colorectal cancer liver metastases by regulating HMGA2 in the nucleus and BMP4/ADAM19 in the cytoplasm
Li, Y., Hu, J., Wang, M., Yuan, Y., Zhou, F., Zhao, H., Qiu, T., & Liang, L. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01124-z · Cited by 36
Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability—Lessons from Colorectal Cancer
Greco, L., Rubbino, F., Buono, A. D., & Laghi, L. (2023) · Genes · doi:10.3390/genes14061169 · Cited by 35
Downregulation of dual‐specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas
Ichimanda, M., Hijiya, N., Tsukamoto, Y., Uchida, T., Nakada, C., Akagi, T., Etoh, T., Iha, H., Inomata, M., Takekawa, M., et al. (2017) · Cancer Science · doi:10.1111/cas.13444 · Cited by 32
Liver transplantation for colorectal liver metastases: What do we need to know?
Line, P., Ruffolo, L. I., Toso, C., Dueland, S., Nadalin, S., & Hernandez‐Alejandro, R. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.03.079 · Cited by 34
Prognosis prediction of stage IV colorectal cancer patients by mRNA transcriptional profile
Wu, B., Yang, J., Qin, Z., Yang, H., Shao, J., & Shang, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.4824 · Cited by 31
CircNOLC1 Promotes Colorectal Cancer Liver Metastasis by Interacting with AZGP1 and Sponging miR‐212‐5p to Regulate Reprogramming of the Oxidative Pentose Phosphate Pathway
Yuan, M., Zhang, X., Yue, F., Zhang, F., Jiang, S., Zhou, X., Lv, J., Zhang, Z., Sun, Y., Chen, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202205229 · Cited by 34
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis
Song, D., Hou, S., Ma, N., Yan, B., & Gao, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1485303 · Cited by 33
Exosome-driven nano-immunotherapy: revolutionizing colorectal cancer treatment
Lahouty, M., Fadaee, M., Shanehbandi, D., & Kazemi, T. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10157-9 · Cited by 31
USP10/XAB2/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancer
Liu, X., Zhang, S., An, Y., Xu, B., Yan, G., & Sun, M. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03357-z · Cited by 31
Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
Yang, Q., Huo, S., Sui, Y., Du, Z., Zhao, H., Liu, Y., Li, W., Wan, X., Liu, T., & Zhang, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00487 · Cited by 32
FDG PET Hybrid Imaging
Becker, J., Schwarzenböck, S. M., & Krause, B. J. (2020) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-42618-7_19 · Cited by 31
The role of melatonin in colorectal cancer treatment: a comprehensive review
Kvietkauskas, M., Žitkutė, V., Leber, B., Strupas, K., Stiegler, P., & Schemmer, P. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920931714 · Cited by 31
The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis
Kawaguchi, Y., & Vauthey, J. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08777-z · Cited by 31
Omics analyses in peritoneal metastasis—utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review
Lund‐Andersen, C., Torgunrud, A., Fleten, K. G., & Flatmark, K. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-136 · Cited by 31
Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy
Jhawat, V., Gulia, M., Gupta, S., Maddiboyina, B., & Dutt, R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.039 · Cited by 32
The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases
Polívka, J., Windrichová, J., Pešta, M., Houfková, K., Řezáčková, H., Macanova, T., Vyčítal, O., Kučera, R., Slouka, D., & Topolčan, O. (2020) · Cancers · doi:10.3390/cancers12092434 · Cited by 30
DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation
Varughese, L. A., Lau‐Min, K. S., Cambareri, C., Damjanov, N., Massa, R. C., Reddy, N. J., Oyer, R. A., Teitelbaum, U. R., & Tuteja, S. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2463 · Cited by 31
DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer
Padder, R. A., Bhat, Z. I., Ahmad, Z., Singh, N., & Husain, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.592130 · Cited by 31
Albuca Bracteate Polysaccharides Synergistically Enhance the Anti-Tumor Efficacy of 5-Fluorouracil Against Colorectal Cancer by Modulating β-Catenin Signaling and Intestinal Flora
Yuan, X., Xue, J., Tan, Y., Yang, Q., Qin, Z., Bao, X., Li, S., Pan, L., Jiang, Z., Wang, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736627 · Cited by 31
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
Shah, M. A., Yoshino, T., Tebbutt, N. C., Grothey, A. F., Tabernero, J. M., Xu, R., Cervantes, A. M. R., Oh, S. C., Yamaguchi, K., Fakih, M., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.11.002 · Cited by 31
Self-citation
Enhanced Early Detection of Colorectal Cancer via Blood Biomarker Combinations Identified Through Extracellular Vesicle Isolation and Artificial Intelligence Analysis
Koo, B., Kim, Y. I., Lee, M., Lim, S., & Shin, Y. M. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70088 · Cited by 32
Comprehensive Review on Colorectal Cancer and Transplant
Prenner, S. B., & Levitsky, J. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14340 · Cited by 29
Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives
Battaglin, F., Dadduzio, V., Bergamo, F., Manai, C., Schirripa, M., Lonardi, S., Zagonel, V., & Loupakis, F. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356815 · Cited by 30
Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 2- Application to Head-and-Neck Cancer Patients
Launay, M., Ciccolini, J., Fournel, C., Blanquicett, C., Dupuis, C., Fakhry, N., Duffaud, F., Salas, S., & Lacarelle, B. (2017) · Clinical Cancer Drugs · doi:10.2174/2212697x04666170817123425 · Cited by 30
Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high-risk colon cancer patients – study protocol for the PIPAC-OPC3 Trial. A prospective, controlled phase 2 Study
Graversen, M., Detlefsen, S., Fristrup, C. W., Pfeiffer, P., & Mortensen, M. B. (2018) · Pleura and Peritoneum · doi:10.1515/pp-2018-0107 · Cited by 30
Self-citation
Cardiovascular complications of metastatic colorectal cancer treatment
Keramida, K., Charalampopoulos, G., Filippiadis, D. K., Tsougos, E., & Farmakis, D. T. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.03.04 · Cited by 30
Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer
Henry, J. T., & Johnson, B. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.08.08 · Cited by 29
Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer
López‐Cortés, A., Paz‐y‐Miño, C., Guerrero, S. X., Jaramillo-Koupermann, G., Cáceres, Á. L., Intriago-Baldeón, D. P., García-Cárdenas, J. M., Guevara‐Ramírez, P., Armendáriz‐Castillo, I., Leone, P., et al. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0102-4 · Cited by 29
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected
Sastre, J., de la Orden, V., Martínez, A., Bando, I., Balbı́n, M., Bellosillo, B., Palanca, S., Peligros, M. I., Mediero-Valeros, B., Llovet, P., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.014 · Cited by 31
DSTYK Promotes Metastasis and Chemoresistance via EMT in Colorectal Cancer
Zhang, J., Miller, Z., Musich, P. R., Thomas, A. E., Yao, Z. Q., Xie, Q. R., Howe, P. H., & Jiang, Y. Q. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01250 · Cited by 30
Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients’ Outcome
Galindo-Pumariño, C., Collado, M., Herrera, M., & Peña, C. (2021) · Cancers · doi:10.3390/cancers13051130 · Cited by 31
Peroxiporins Are Induced upon Oxidative Stress Insult and Are Associated with Oxidative Stress Resistance in Colon Cancer Cell Lines
Gašparović, A. Č., Milković, L., Rodrigues, C., Mlinarić, M., & Soveral, G. (2021) · Antioxidants · doi:10.3390/antiox10111856 · Cited by 30

Authors: Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W. J. G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T. J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H. J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., & Arnold, D.
Affiliations: Universitat de València (ES)
Hôpital Paul-Brousse (FR)
Ospedale Policlinico San Martino (IT)
Tel Aviv University (IL)
University of Turin (IT)
Northwestern Medicine (US)
Unified Szent István and Szent László Hospital (HU)
University of Campania "Luigi Vanvitelli" (IT)
Institut de Cancérologie de l'Ouest (FR)
Université Paris-Saclay (FR)
University of Pisa (IT)
Mayo Clinic (US)
Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
KU Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
Universidade de São Paulo (BR)
Klinikum Oldenburg (DE)
Ospedale Papa Giovanni XXIII (IT)
Chinese University of Hong Kong (HK)
University of Oxford (GB)
Aichi Cancer Center (JP)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Institute of Cancer Research (GB)
Bank of Cyprus Oncology Center (CY)
University of Ioannina (GR)
Odense University Hospital (DK)
Queen Elizabeth Hospital (AU)
Amsterdam UMC Location University of Amsterdam (NL)
University Hospital Magdeburg (DE)
University Hospital of Geneva (CH)
Institut Català d'Oncologia (ES)
Comprehensive Cancer Center Vienna (AT)
Martin Luther University Halle-Wittenberg (DE)
Vall d'Hebron Hospital Universitari (ES)
Universitair Ziekenhuis Leuven (BE)
Imperial College Healthcare NHS Trust (GB)
National Cancer Center Hospital East (JP)
Hôpital Européen Georges-Pompidou (FR)
ORCID: Cervantes, A.
Adam, R.
Sobrero, A.
Bardelli, A.
Benson, A.
Bodoky, G.
Ciardiello, F.
Douillard, J.-Y.
Ducreux, M.
Falcone, A.
Grothey, A.
Gruenberger, T.
Haustermans, K.
Heinemann, V.
Hoff, P.
Labianca, R.
Ma, B.
Maughan, T.
Muro, K.
Normanno, N.
Oyen, W.J.G.
Papamichael, D.
Pentheroudakis, G.
Pfeiffer, P.
Price, T.J.
Punt, C.
Ricke, J.
Salazar, R.
Schmoll, H.J.
Tabernero, J.
Tejpar, S.
Wasan, H.
Yoshino, T.
Zaanan, A.
Arnold, D.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 27
Issue: 8
Pages: 1386-1422
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdw235
OpenAlex: W2470575266
Cited by: 3,421
References: 309
Citations by year: 2026: 199 · 2025: 236 · 2024: 297 · 2023: 364 · 2022: 481 · 2021: 518 · 2020: 444 · 2019: 365 · 2018: 279 · 2017: 189 · 2016: 39
FWCI: 155.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1191 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Lirias (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
Funders: Cancer Research UK (13363)
National Institute for Health and Care Research (11/100/50)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, colorectal cancer, surgical resection of metastases, systemic therapy, multidisciplinary management, treatment decision-making, evidence-based recommendations
MeSH terms: Humans, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Guidelines as Topic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks